Bank of America 8-K 2017
As filed with the Securities and Exchange Commission on December 14, 2017
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 14, 2017
BANK OF AMERICA CORPORATION
(Exact name of registrant as specified in its charter)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On December 14, 2017, the board of directors (the “Board”) of Bank of America Corporation (the “Corporation”) appointed Dr. Maria T. Zuber to serve on the Board effective immediately, and also appointed Dr. Zuber to serve on the Board's Enterprise Risk and Corporate Governance Committees. Dr. Zuber is Vice President for Research at the Massachusetts Institute of Technology and a Senior Research Scientist at the National Aeronautics and Space Administration. Dr. Zuber serves on the board of directors of Textron Inc., a diversified manufacturer. Dr. Zuber will receive compensation as a non-employee director in accordance with the Corporation’s non-employee director compensation program described under the caption “Director Compensation” in the Corporation’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 15, 2017. Under the non-employee director compensation program, Dr. Zuber will be granted restricted stock and cash awards on December 14, 2017, the amount of which will be prorated from the date of appointment to the Corporation’s next annual stockholders’ meeting.
A copy of the Corporation’s news release announcing the appointment of Dr. Zuber is furnished as Exhibit 99.1 and is incorporated in this report by reference.
ITEM 9.01. Financial Statements and Exhibits.
The following exhibit is filed herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 14, 2017